Siemens Faces Dual Pressure from Regulatory Delays and Investment Threats

Siemens delays key Healthineers stake reduction vote to 2027 for tax clarity, continues buybacks. CEO warns EU AI rules risk diverting €1B investment to US & China.

Siemens shareholders will have to wait until 2027 for a pivotal vote on the company's planned reduction of its stake in Siemens Healthineers. The spin-off of roughly 30 percent of the medical technology unit directly to shareholders, which would lower Siemens' holding from about 67 percent to a minority position, has been delayed. Management is awaiting confirmation from German tax authorities that the transaction can proceed on a tax-neutral basis under national conversion law, pushing the vote to the ordinary Annual General Meeting in February 2027.

The postponement disappointed investors banking on a quicker unlocking of value. Siemens shares closed at 242.55 euros on Monday, nearly 7 percent below their 52-week high of 261.55 euros. Despite the delay, the company continues its capital return program, having repurchased over 26 million of its own shares since the program began in February 2024. In the past week alone, it bought back nearly 640,000 shares exclusively via Xetra. Analysts view this volume as a signal of robust free cash flow, providing a buffer against market volatility reflected in an annualized 30-day volatility of almost 45 percent.

Concurrently, CEO Roland Busch issued a stark warning to European Union policymakers at the Hannover Messe industrial fair. He stated that if Brussels does not adjust its current AI rulebook, planned investments of around one billion euros will flow primarily to the United States and China. Busch criticized the EU AI Act for incorrectly equating industrial applications in factories with consumer-oriented software, arguing that newly created oversight layers burden sectors already subject to strict industry rules. He deemed recent EU Commission proposals for simplification insufficient to remove these structural hurdles.

This regulatory pressure comes as Siemens deepens its transformation into a software powerhouse, with software now accounting for over a third of its revenue. The company has backed this shift with major acquisitions, spending a combined $15 billion US dollars on strategic purchases like Altair and Dotmatics in recent years. At the trade fair, Siemens showcased tangible results of this strategy, including the Digital Twin Composer developed with Nvidia—already deployed at food giant PepsiCo—and a new AI-capable data center for industrial automation created with Palo Alto Networks.

Market analysts hold mixed views on the stock's trajectory. RBC Capital Markets maintained a "Sector Perform" rating with a price target of 270 euros on April 20, acknowledging the strategic value of the Healthineers separation while conceding the slower pace may disappoint short-term investors. Goldman Sachs has a price target of 235 euros but views the company as fundamentally well-positioned, forecasting earnings per share of approximately 10.97 euros for fiscal year 2026.

Technically, the share price is holding a crucial line, trading just above its 200-day moving average around 236 euros. A break below this level could invite further selling pressure. The next major test arrives on May 13, when Siemens reports its second-quarter results. This will be the first earnings report under new CFO Veronika Bienert, who took over from Ralf Thomas in early April. Investors will scrutinize whether the massive software investments are translating into tangible profits and if the record order backlog of around 114 billion euros at the Digital Industries segment is being efficiently converted into revenue.